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Abstract 
Low-frequency ultrasound application is known to increase the 
skin’s permeability to large molecules such as vaccines, and to enable 
transcutaneous immunisation.  Sodium dodecyl sulphate (SDS) – a skin 
irritant - is often included in the coupling medium at 1% w/v, as this has 
been found to enhance skin permeability.  In this paper we show, for the 
first time, the feasibility of low-frequency ultrasound-assisted 
transcutaneous immunisation in the absence of SDS.  Antibody titres were 
strongly influenced by experimental conditions. SDS presence in the 
coupling medium increased antibody titres, though a lower concentration of 
0.5% w/v generated much higher titres than the commonly used 1%w/v, 
despite causing less skin damage. A lower ultrasound duty cycle of 10% 
generated higher antibody titres than a duty cycle of 20%, also despite 
causing lower skin damage.  Such lack of correlation between skin damage 
and immune responses indicates that enhancement of skin permeability to 
topically-applied antigen (as indicated by changes in skin integrity) was not 
the main mechanism of low-frequency ultrasound-assisted skin 
immunisation. 
 
 
 
Keywords: low frequency ultrasound, immunisation, transcutaneous, duty 
cycle, SDS concentration, skin damage 
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1. Introduction 
Immunisation by topical application of vaccine or antigen on to the 
skin has the advantages of avoiding needle-associated problems such as risk 
of blood-borne transmission, needle-related pain, phobia and other injuries, 
which is expected to increase patient compliance and vaccine coverage.  
However, because the skin is a good barrier, its permeability to topically 
applied substances may need to be increased to obtain optimal immune 
responses by this route, and various techniques are being investigated.  One 
such method is the application of low frequency ultrasound to the skin via a 
liquid coupling medium (Mitragotri & Kost 2004; Machet & Boucaud 
2002).   
While the literature on ultrasound-induced transdermal drug delivery 
is substantial, that on ultrasound-assisted transcutaneous immunisation is 
scant and includes a few reports on ultrasound-assisted vaccination in fish, 
for application in fish farming (Fernandez-Alonso et al., 2001; Zhou et al., 
2002a-b; Navot et al., 2004), a report on the role of the macrophage system 
in the mediation of the immunostimulating effects of low frequency 
ultrasound (Khodareva & Sizyakina 1991) and a paper on transcutaneous 
vaccination in mice (Tezel et al., 2005).  In the latter study, the authors 
showed enhanced levels of serum antibody titres, following topical 
application of antigen on to skin pre-treated with low-frequency ultrasound 
in the presence of sodium dodecyl sulphate (SDS).  The anionic surfactant 
SDS has been shown to increase skin permeabilisation and enhance 
ultrasound-assisted transcutaneous delivery; in in vitro studies using pig 
skin, permeability to mannitol was increased 200-fold when SDS was 
included in the coupling medium compared to an 8-fold increase for 
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ultrasound only (Mitragotri et al., 2000). This study also showed that 
ultrasound enhanced SDS permeation into the skin and it has been suggested 
that ultrasound application increased SDS dispersion in the stratum corneum 
(as opposed to its localisation in aggregates), which would result in a greater 
fraction of the stratum corneum exposed to SDS (Mitragotri et al., 2000; 
Tezel et al., 2002).  More recently, Lavon et al., (2005) showed that when 
skin was concomitantly exposed to ultrasound and SDS, its pH decreased.  
This led the authors to propose that at the lower skin pH, SDS can permeate 
to a greater extent into the skin and thereby exert a greater disrupting effect, 
due to its existence as the free fatty acid at low pH and thus greater 
solubility in the stratum corneum lipids.  
The scant literature on low-frequency ultrasound-assisted skin 
vaccination means that the influence of many experimental parameters, such 
as animal species, the nature and volume of coupling medium, ultrasound 
duty cycle and sonication time, on the immune responses is poorly 
understood.  In this paper, we have investigated the influence of i) 
ultrasound duty cycle, ii) SDS presence and iii) its concentration in the 
coupling medium, on immune responses in mice following transcutaneous 
immunisation with tetanus toxoid (TTxd). We have also explored 
relationships between the extent of ultrasound-induced skin damage and 
anti-tetanus immune responses.  Pre-treatment of skin with ultrasound prior 
to antigen application, as opposed to concurrent antigen and ultrasound 
application (when the antigen is present in the coupling medium), is 
possible due to the fact that the skin remains highly permeabilised for a 
number of hours following ultrasound application (Mitragotri et al., 1996) 
and has the advantage of avoiding exposure of antigen to potentially 
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damaging ultrasound waves. Control experiments where the antigen was 
administered intramuscularly (i.m.) or topically to intact skin (in the absence 
of ultrasound) were also performed. In a third control group, skin was pre-
treated with a solution of SDS only prior to topical antigen administration. 
The presence and extent of skin damage was assessed by in vivo 
measurement of trans-epidermal water loss (TEWL) – an indicator of skin 
integrity (Nangia et al., 2005) – and/or by histological examination of skin 
biopsies following immunisation using the various ultrasound protocols. 
Systemic immune responses were analysed by ELISA to detect antigen-
specific IgG and by in vivo toxin neutralisation assays in mice to determine 
levels of functional tetanus toxin-neutralising antibodies. 
 
2 Materials and Methods 
2.1 Animals 
Adult female Balb/C and NIH mice used for immunisation at The 
School of Pharmacy and for the in vivo challenge studies at the National 
Institute for Biological Standards and Control (NIBSC) respectively were 
purchased from Harlan (Oxon, U.K.). Where necessary, all animal 
procedures were approved by The School of Pharmacy’s or the NIBSC’s 
Ethical Review Committee and were performed in accordance with the 
Animals (Scientific Procedures) Act 1986.  The animals were given food 
and water ad libitum during the course of the experiments. 
 
2.2 Materials  
Tesa® economy double-sided tape was obtained from RS Ltd. 
(Northants, UK).  Ketaset® injection (containing 100 mg/mL of ketamine 
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hydrochloride with benzethonium chloride 0.01% as a preservative) was 
obtained from Fort Dodge Animal Health Ltd. (Southampton, UK) and 
Xylazine 2% was purchased from Milipledge Veterinary (Nottinghamshire, 
UK).  Sodium dodecyl sulphate, Tween® 20, 2,2’-Azino-bis(3-
Ethylbenzthiazoline-6-sulfonic acid) (ABTS) tablets (diammonium salt) and 
hydrogen peroxide (30 % v/v) were purchased from Sigma-Aldrich 
Company Ltd (Poole, UK). Disodium hydrogen orthophosphate, potassium 
dihydrogen orthophosphate and sodium chloride, used to prepare phosphate 
buffered saline (PBS), were all analytical grade and purchased from VWR 
International Ltd. (Poole, Dorset, UK).  PBS tablets were purchased from 
Oxoid Ltd, Basingstoke. Citric acid was from Fisher, UK, and the rabbit 
anti-mouse IgG-horseradish peroxidise conjugate was obtained from Sigma-
Aldrich Company Ltd. (Poole, UK). Nunc™ Maxisorb Immuno ELISA 
plates were obtained from Thermo Fisher Scientific (Loughborough, UK).  
For immunisation and coating of ELISA plates, purified non-adsorbed 
tetanus toxoid (NIBSC code  02/126, 12.5 mg/ml, 5000 flocculating units 
[Lf] per ml) was used. For ELISA, an in-house reference serum with a 
tetanus antitoxin potency of 1.68 IU/ml was used. For the in vivo toxin 
neutralisation test, the International Standard for Tetanus Anti-toxin, Equine 
(NIBSC catalogue number TE-3, 120 IU/ampoule) was used as the 
reference.  
 
2.3 Assessment of ultrasound-induced skin damage  
Balb/c mice (6-8 weeks old, whose abdominal fur had been removed 
using electric clippers 24h previously), in groups of 5, were anaesthetised 
using an intra-peritoneal injection of a mixture of 0.9 ml/kg of ketamine 
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HCl solution (100 mg/ml) and 0.5 ml/kg of xylazine solution (20 mg/ml), 
and were placed on their back. The baseline pre-sonication TEWL was 
measured using the condenser-chamber evaporimeter, AquaFluxTM (BIOX 
Ltd, UK). Subsequently, a custom-built flanged cylinder was attached to the 
shaved abdomen using double-sided tape (Tesa, UK) and firmly held by a 
clamp fixed to a retort stand.  The sonicator probe was lowered into the 
flanged cylinder and placed at 7.5mm from the skin. The flanged cylinder 
was then filled with 20 mL of the coupling medium (water or SDS aqueous 
solution at concentrations 0.5 or 1 % w/v), and pulses of ultrasound waves 
(20 kHz, generated by VCX500 at 20% machine amplitude, Sonics & 
Material Inc, USA) were applied for a total sonication period of 45 s. 
Ultrasound was applied with a duty cycle of 10 or 20% (i.e. 0.1s on 0.9s off 
or 0.2s on 0.8s off respectively).  The ultrasound protocols 1-4 described in 
Table 1 were used.  After sonication, the ultrasound probe, coupling 
medium and the flanged cylinder were removed, and the abdominal skin 
was washed with 500 mL of water and wiped dry with tissue paper. For the 
three groups exposed to an ultrasound duty cycle of 20%, the skin TEWL 
was measured at 5, 15, 30, 45 and 60 minutes post-sonication, to determine 
the effect of sonication on TEWL and the post-sonication recovery.  At the 
end of the experiment, animals were killed by exposure to carbon dioxide 
gas and skin biopsies were taken. The biopsies were treated with formalin 
and alcohol, embedded in paraffin wax, sectioned, stained with 
haematoxylin and eosin and examined with light microscopy to determine 
the effect of ultrasound and SDS concentration on skin damage.  For the 
group exposed to an ultrasound duty cycle of 10%, skin damage was only 
evaluated by examination of skin biopsies prepared as described above. 
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2.4 Transcutaneous immunisation  
  For transcutaneous immunisation, Balb/c mice were shaved, 
anaesthetised and exposed to ultrasound as described in Section 2.3. After 
sonication, the ultrasound probe, coupling medium and the flanged cylinder 
were removed, and the abdominal skin was washed and wiped dry as 
described in Section 2.3. Mice (in groups of 5) were then immunised by 
pipetting one hundred µl of purified non-adsorbed tetanus toxoid 
(containing 30 Lf, 75 µg of TTxd in PBS per dose) on to the prepared skin 
surface. The antigen solution was spread over the prepared skin area using a 
gloved finger, and left in place for one hour.  Subsequently, the mouse 
abdominal skin was washed with lukewarm tap water, dried and the mouse 
was returned to its cage.  The procedure was repeated with the same antigen 
dose on days 15 and 46 to administer the first and second booster antigen 
doses respectively and the animals were bled on days 14, 45 and 60 via the 
tail vein to determine antibody levels. Blood samples were allowed to 
coagulate at 5°C overnight before separating the serum by centrifugation at 
5000rpm for 10 minutes.  The serum was collected and stored at -20ºC until 
assayed for antibody levels by enzyme linked immunosorbent assay 
(ELISA) or in vivo toxin neutralisation test as described in Sections 2.5-2.6 
below.    
In control experiments, 2 groups of mice (n=5 in each group) were 
treated as above, except that ultrasound was not applied.  Instead, mouse 
skin was exposed to 20mL of either PBS or 1% w/v SDS solution for 5 min 
prior to antigen application for 1h.  As a positive control, one group of mice 
was immunised i.m. with 50 µL of the antigen solution (containing 2 Lf, 5 
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µg of TTxd in PBS) in the hind leg. Animals were bled and received booster 
antigen doses as described above.  The different immunisation protocols are 
summarised in Table 1. 
 
2.5 Determination of anti-tetanus toxoid IgG titres using ELISA 
To measure the total anti-TTxd IgG responses an equal volume of 
serum was pooled for each of the 5 animals in the group and analysed by 
ELISA. 96-well ELISA microplates were coated with 100 µl per well of 
purified TTxd (0.5 Lf/ml in 0.05M carbonate buffer pH 9.6) and incubated 
at 4°C overnight. The ELISA plates were then washed three times in PBS 
containing 0.05% v/v Tween-20 (PBS-T) and dried by blotting onto 
absorbent paper towel. The plates were then blocked with 150 µl of PBS-T 
containing 5% w/v skimmed milk powder (Marvel) for 1 h at 37°C. The 
plates were washed as described previously and serial two-fold dilutions of 
test and reference serum (diluted in PBS-T containing 1% skimmed milk 
powder) were prepared across the plate. The final volume of serum in each 
well was 100 µl. The plates were then incubated for 2 h at 37°C. After 2 h, 
plates were wash d as described previously and antigen specific IgG 
antibodies were detected using a horseradish peroxidase-conjugated rabbit 
anti-mouse IgG diluted 1/2000 in PBS-T containing 1% w/v skimmed milk 
powder (100 µl per well). After a further incubation at 37°C for 1 h, and a 
final wash, the chromogen solution (prepared immediately before use by 
dissolving 1 ABTS tablet in 20 ml 0.05 M citric acid buffer, pH 4.0 and 
adding 5 µl of 30% v/v hydrogen peroxide solution) was added and the 
reaction was allowed to develop for 30 min. The optical density was then 
measured at 405 nm (A405) using a Multiscan ELISA plate reader (Thermo 
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Life Sciences, UK). Antibody responses were analysed by an in-house 
parallel line bioassay program using a minimum of 3 points for test and 
reference samples. ANOVA was used to test the significance of departures 
from linearity and parallelism. The anti-TTxd IgG titres were expressed in 
IU/ml against the in-house reference mouse serum. 
    
2.6 Protection against tetanus following in vivo challenge 
In order to confirm whether the serum IgG from immunized mice 
was protective against tetanus toxin, passive challenge studies were 
performed in groups of female NIH mice using the onset of paralysis as the 
end point. The potency of tetanus antitoxin in the test serum sample was 
determined by comparing the dose necessary to protect mice against the 
paralytic effects of a fixed dose of tetanus toxin with the quantity of a 
reference tetanus antitoxin required to give the same protection.  A series of 
dilutions of the reference antitoxin (International Standard for Tetanus Anti-
toxin, Equine TE-3) and of pooled serum samples from each group were 
prepared in gelatin-phosphate buffered saline (GPBS) at concentrations of 
0.0007 – 0.002 IU/ml. A fixed volume of purified tetanus toxin solution 
(containing approximately 50 mouse paralytic doses (50 x PD50) was then 
added to all samples and the mixtures were allowed to stand for 30 minutes 
at room temperature to allow toxin neutralisation to occur. Mice (in groups 
of 4) were then injected subcutaneously in the hind leg with 0.5 ml of 
toxin/antitoxin mixture and observed over a 96 h period for signs of 
paralysis. The protective capacity of the test mouse serum samples was 
compared against the ability of the reference antitoxin to confer protection 
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against the paralytic effects of the tetanus toxin in 50% of the animals.  
Tetanus antitoxin concentrations were expressed in IU/mL.  
 
 
2.7 Statistical analyses 
Statistical analyses were performed using SPSS software version 15 
(SPSS Inc.) to determine the influence of ultrasound application on TEWL. 
Paired t-tests between TEWL at 0 and 5 minutes were conducted to 
determine the immediate change in TEWL upon sonication.  To statistically 
assess the influence of SDS presence and its concentration on TEWL 
recovery with time post-sonication, repeated measures ANOVA was 
conducted on TEWL values for 5-60 minutes.  Results were considered 
statistically significant when p<0.05.   
 
 
3.  Results and Discussion 
 
3.1 Influence of SDS concentration and duty cycle on ultrasound-
induced changes to skin integrity in vivo 
In order to identify possible relationships between ultrasound-
induced changes to the skin’s structural integrity (which is expected to be 
related to antigen flux into the skin) and immune responses, the impact of 
SDS presence and concentration in the coupling medium and ultrasound 
duty cycle on in vivo skin integrity (indicated by TEWL and histological 
examination of excised skin) was determined. 
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In the absence of SDS in the coupling medium, the mild Protocol 1 
(<1min of sonication applied in brief (0.2s) pulses separated by fairly long 
intervals (4x pulse duration) using a large volume (20mL) of coupling 
medium) caused a small (less than 2x) but statistically significant increase in 
TEWL (p<0.05, paired t test between time 0 and 5 min, Figure 1) which 
returned to baseline levels after 1h, and histological examination showed no 
obvious disruption of the skin barrier (Figure 2b compared to Figure 2a).  
Inclusion of SDS in the coupling medium caused a larger (4-5x) increase in 
TEWL, whose magnitude and recovery was related to SDS concentration 
(Figure 1, repeated measures ANOVA, p<0.05). The greater increase in 
post-sonication TEWL and lack of recovery after 1h by the higher (1%w/v) 
SDS concentration was reflected in histological assessment, where vertical 
channels in the skin were revealed (Figures 2d).  Increased in vivo skin 
damage in the presence of SDS reflects previous in vitro reports on 
enhanced skin conductivity by ultrasound/SDS combinations (Mitragotri et 
al., 2000).  The negative effect of 1% SDS on skin integrity could be 
reduced by a milder (10% versus 20% duty cycle) ultrasound protocol, as 
shown in Figure 2e. The stratum corneum was visible, without any loss, 
there were no vertical ‘channels’ that were observed in skin sonicated with a 
20% cycle, and the micrograph was similar to that of control non-sonicated 
skin (Figure 2a).  Lesser skin damage with the lower duty cycle could be 
due to some skin recovery during the longer (0.9 vs 0.8s) pulse interval from 
any damage incurred during the much shorter (0.1 vs 0.2s) pulse and a lower 
rate of increase in the coupling medium temperature (Dahlan et al., 2005) 
which would limit any heat-associated adverse effects on skin integrity.   
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3.2 Anti-tetanus toxoid IgG and neutralising antibody responses 
following parenteral or topical antigen administration in mice 
 
3.2.1  Topical antigen application to intact skin in the absence of ultrasound 
The primary responses were below the limit of detection, and the 
secondary responses are shown in Figure 3 and in Table 2.   In the absence 
of ultrasound (protocols 5-6), IgG titres remained low or undetectable 
(Figure 3), correlating with previous reports on antigen application to intact 
skin, in the absence of adjuvants (Tierney et al., 2003, Glenn et al., 1998; 
Strid et al., 2004; Godefroy et al., 2005).  Interestingly, the observed failure 
of SDS skin pre-treatment to enable transcutaneous immunisation is in 
contrast to a previous report that showed antibody titres to hen lysozyme 
antigen when the latter was applied to shaved mouse skin pre-treated with 
100 µL of SDS solution for 10 minutes (Huang et al., 2006). The positive 
results by Huang et al. could have been due to much higher SDS 
concentrations used (though the concentration is unclear, being reported as 
0.1-5.0% v/v - without an indication of the SDS concentration in the stock 
solution), the smaller hen eggwhite lysozyme antigen (∼10x smaller than 
tetanus toxoid), and the use of a patch over the antigen formulation.  Patch 
application could have increased skin hydration, known to increase skin 
permeability (Zhai & Maibach 2005). Other studies in mice have shown 
protective response to tetanus merely by prolonging the duration of antigen 
contact with skin by use of a patch (Naito et al., 2007). 
 
3.3.2 Ultrasound-assisted transcutaneous immunisation  
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Pre-treatment of mouse skin with ultrasound (with PBS as the 
coupling medium, protocol 1) prior to topical antigen application induced 
significant levels of anti-TTxd IgG and protective toxin-neutralising 
antibodies, although responses were still more than 30-fold lower when 
compared to those induced by conventional parenteral immunization (Figure 
3, Table 2). However, the levels of protective toxin-neutralising antibodies 
were above those considered necessary for protection against tetanus in 
humans (Balmer et al., 2007).   Achieving protective levels of anti-tetanus 
immune responses following antigen application to ultrasound-pretreated 
skin, in the absence of SDS in the coupling medium, or adjuvant, shows the 
promise of ultrasound for skin immunisation, and further study with other 
antigens and in other species is merited.   For ultrasound-assisted skin 
permeabilisation, SDS is often included in the coupling medium at 1% w/v, 
(Tezel et al., 2004; Mitragotri & Kost 2001; Tezel et al., 2005), despite the 
fact that it is a skin irritant (Agner & Serup 1990), especially when applied 
concomitantly with other irritants (Fluhr et al., 2005). However, we show 
for the first time the feasibility of using low-frequency ultrasound for skin 
immunisation, in the absence of SDS.  It seems that application of low-
frequency ultrasound, even in the absence of SDS in the coupling medium, 
enables sufficient antigen to permeate into the skin to be taken up by the 
cells of the skin immune system.  Alternatively, it may be that topical 
ultrasound application, which is known to increase epidermal Langerhans 
cell density (Tezel et al., 2005), stimulated the skin immune system 
sufficiently such that a relatively low permeation of the antigen into the skin 
could result in considerable antibody titres.   
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When SDS was included in the ultrasound coupling medium (20% duty 
cycle, protocols 2-3), the anti-tetanus IgG and neutralising antibody titres 
were increased further, reflecting the synergistic effects of ultrasound and 
SDS on skin permeability to topically applied drugs (Mitragotri et al., 2000; 
Tezel et al., 2002).  However, the increase in antibody titres was inversely 
proportional to the SDS concentration in the medium (Figure 3, Table 2), 
and did not correlate with the extent of skin damage observed in the 
presence of SDS (Figures 1, 2c-d). The highest immune responses were seen 
in the presence of 0.5% w/v SDS and, after 3 antigen doses, IgG and 
neutralising antibody titres were 12-fold higher than those obtained with 
ultrasound alone and only 3-4fold lower than those induced by conventional 
i.m. injection of antigen.  Doubling the SDS concentration in the coupling 
medium (to 1% w/v) had a negative effect on antibody titres, with a 4-5 fold 
reduction in anti-TTxd IgG and neutralising antibody titres. This suggests a 
possible detrimental effect of SDS presence in the coupling medium on 
antigen integrity.  Ultrasound application in the presence of SDS is known 
to reduce the pH of the deeper skin layers (Lavon et al., 2005), and low pH 
reduces the structural integrity and antigenicity of tetanus toxoid (Xing et 
al., 1996).  
 
The lack of correlation between observed changes in the structural 
integrity of the skin barrier and immune responses was again seen in mice 
immunised in the presence of a reduced ultrasound duty cycle of 10% 
(protocol 4). In the presence of 1% SDS, the lower duty cycle of 10% 
generated two-fold higher IgG and neutralising antibody titres than those 
obtained with the higher ultrasound duty cycle at the same SDS 
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concentration (Figure 3, Table 2). This lower ultrasound duty cycle did not 
induce the structural changes in the skin barrier observed with the higher 
cycle and the same SDS concentration  (Figure 2d-e) providing further 
evidence that the antibody responses may not be related solely to the 
permeability and hence antigen dose in the skin. Other factors such as the 
extent of stimulation of the skin immune system are likely to play an 
important role in the response to skin immunisation.  It was mentioned 
earlier that ultrasound application on its own, in the absence of antigen, 
increases epidermal Langerhans cell density (Tezel et al., 2005).  What is 
not known is the influence of ultrasound protocols on such stimulation of 
Langerhans cells.  A greater stimulation of Langerhans cells could have 
occurred by the 10% duty cycle ultrasound due to the longer duration over 
which ultrasound was applied - a period of 450 seconds - in contrast to half 
that duration for the 20% duty cycle to obtain a total sonication time of 45s 
in both cases.  Greater stimulation of the Langerhans cells could compensate 
for lower antigen presence in the skin.  This requires further investigation. 
 
 
4. Conclusions 
We have shown that application of tetanus toxoid to skin pre-treated 
with low-frequency ultrasound resulted in anti-tetanus toxoid IgG and 
neutralising antibody titres that were above those required for protection 
against tetanus, even in the absence of SDS in the coupling medium.  This 
indicates that SDS – a skin irritant - may not be required for low-frequency 
ultrasound assisted transcutaneous immunisation.  SDS presence in the 
coupling medium at 0.5 or 1% w/v increased antibody titres, though the 
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increase was inversely related to SDS concentration, despite lower skin 
damage caused by the lower SDS concentration.  Ultrasound duty cycle (10 
or 20%) was also found to influence antibody titres, the lower duty cycle 
generating two-fold higher IgG and neutralising antibody titres, again 
despite lower skin damage.  This indicates that enhancement of skin 
permeability to topically-applied antigen (as indicated by changes in skin 
integrity) was not the main mechanism of low-frequency ultrasound-assisted 
skin immunisation. 
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Figure legends and Table headings 
 
Figure 1: In vivo TEWL from mouse skin when different coupling media 
were used.  PBS (×); 0.5% w/v SDS solution (■) and 1% w/v SDS solution 
(▲).   Time 0 shows baseline (before sonication) TEWL values.  Means and 
standard deviation bars are shown, n=5. 
 
Figure 2: Micrographs showing the influence of SDS concentration in the 
coupling medium and ultrasound duty cycle on skin integrity; A) control 
(non-sonicated skin), B-D) skin  pre-treated with ultrasound 20% duty cycle 
using as coupling medium: B) PBS, C) 0.5%w/v SDS, D) 1%w/v SDS, and 
E) skin pre-treated with 10% duty cycle ultrasound using 1%w/v SDS as 
coupling medium.  Bar represents 100µm. 
 
 
Figure 3. Total anti-TTxd IgG responses in mice following immunisation 
via parenteral and transcutaneous routes (see Table 1 for full details). 
Immune responses were measured by ELISA using pooled serum from all 
animals in each group. Data are anti-TTxd IgG (with 95% confidence 
limits) calculated by parallel line analysis and expressed in IU/ml against an 
in-house mouse reference serum. 
 
 
 
Table 1. Immunisation protocols for parenteral and transcutaneous 
immunisation of mice. Ultrasound was applied with a duty cycle of 20% 
(0.2s on 0.8s off) or 10% (0.1s on 0.9 s off) for a total sonication time of 
45s, using 20ml of coupling medium (PBS or 0.5 or 1% w/v SDS solution), 
with the ultrasound probe at 7.5mm from the skin. 
 
Table 2. Day 60 neutralising antibody responses in mice following 
immunisation via parenteral and transcutaneous routes (see Table 1 for full 
details). Immune responses were measured by ELISA using pooled serum 
from all animals in each group. Data are in IU/ml against a reference tetanus 
antitoxin. N.D= not determined. 
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Figure 1: In vivo TEWL from mouse skin when different coupling media 
were used.  PBS (); 0.5% w/v SDS solution (■) and 1% w/v SDS solution 
(▲).  Time 0 shows baseline (before sonication) TEWL values.  Means and 
standard deviation bars are shown, n=5.
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Figure 2: Micrographs showing the influence of SDS concentration in the 
coupling medium and ultrasound duty cycle on skin integrity; A) control 
(non-sonicated skin), B-D) skin pre-treated with ultrasound 20% duty cycle 
using as coupling medium: B) PBS, C) 0.5%w/v SDS, D) 1%w/v SDS, and 
E) skin pre-treated with 10% duty cycle ultrasound using 1%w/v SDS as 
coupling medium.  Bar represents 100m.
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Figure 3. Total anti-TTxd IgG responses in mice following immunisation 
via parenteral and transcutaneous routes (see Table 1 for full details). 
Immune responses were measured by ELISA using pooled serum from all 
animals in each group. Data are anti-TTxd IgG (with 95% confidence 
limits) calculated by parallel line analysis and expressed in IU/ml against an 
in-house mouse reference serum.
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Table 1. Immunisation protocols for parenteral and transcutaneous 
immunisation of mice. Ultrasound was applied with a duty cycle of 20% 
(0.2s on 0.8s off) or 10% (0.1s on 0.9 s off) for a total sonication time of 
45s, using 20ml of coupling medium (PBS or 0.5 or 1% w/v SDS solution), 
with the ultrasound probe at 7.5mm from the skin.
Immunisation 
protocol
Immunisation 
route
Skin Pre-treatment
Prior to application of antigen
1 Transcutaneous Ultrasound 20% duty cycle + PBS
2 Transcutaneous Ultrasound 20% duty cycle + SDS 0.5% w/v
3 Transcutaneous Ultrasound 20% duty cycle + SDS 1.0% w/v
4 Transcutaneous Ultrasound 10% duty cycle + SDS 1.0% w/v
5 Transcutaneous PBS
6 Transcutaneous SDS 1.0% w/v
7 i.m. N/A
Table(s)
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Table 2. Day 60 neutralising antibody responses in mice following 
immunisation via parenteral and transcutaneous routes (see Table 1 for full 
details). Immune responses were measured by ELISA using pooled serum 
from all animals in each group. Data are in IU/ml against a reference tetanus 
antitoxin. N.D= not determined.
Immunisation 
protocol
In vivo anti-tetanus 
neutralising antibody 
titres (IU/mL)
1 Ultrasound 20% duty cycle + PBS 0.62
2 Ultrasound 20% duty cycle + SDS 0.5% w/v 7.75
3 Ultrasound 20% duty cycle + SDS 1.0% w/v 1.54
4 Ultrasound 10% duty cycle + SDS 1.0% w/v 3.58
5 PBS N.D
6 SDS 1.0% w/v <0.08
7 Intramuscular 29.69
